Vitamin D Supplementation and Calcium Absorption During Caloric Restriction: a Randomized Double-blind Trial
Overview
Authors
Affiliations
Background: Weight loss (WL) is associated with a decrease in calcium absorption and may be one mechanism that induces bone loss with weight reduction.
Objective: Because vitamin D supplementation has been shown to increase true fractional calcium absorption (TFCA), the goal of this study was to examine the effect of vitamin D during WL or weight maintenance (WM).
Design: A randomized, placebo-controlled, double-blind 6-wk study was conducted in 82 postmenopausal women [BMI (in kg/m(2); ±SD): 30.2 ± 3.7] with 25-hydroxyvitamin D [25(OH)D] concentrations <70 nmol/L during either WL or WM. All women were given 10 μg vitamin D(3)/d and 1.2 g Ca/d and either weekly vitamin D(3) (375 μg) or a placebo equivalent to 63 μg (2500 IU)/d and 10 μg (400 IU)/d, respectively. We measured TFCA with the use of dual-stable isotopes, 25(OH)D, parathyroid hormone, estradiol, calcitriol, and urinary calcium at baseline and 6 wk in weight loss and vitamin D(3)-supplementation (WL-D; n = 19), weight maintenance and vitamin D(3)-supplementation (WM-D; n = 20), weight loss and placebo (n = 22), and weight maintenance and placebo (n = 21) groups.
Results: WL groups lost 3.8 ± 1.1% of weight with no difference between vitamin D(3) supplementation and the placebo. The rise in serum 25(OH)D was greatest in the WL-D group (19.8 ± 14.5 nmol/L) compared with in WM-D (9.1 ± 10.3 nmol/L) and placebo groups (1.5 ± 10.9 nmol/L). TFCA increased with vitamin D(3) supplementation compared with placebo treatment (P < 0.01) and decreased during WL compared with WM. Serum 25(OH)D or 1,25-dihyroxyvitamin D did not correlate with TFCA.
Conclusion: These data show that vitamin D supplementation increases TFCA and that WL decreases TFCA and suggest that, when calcium intake is 1.2 g/d, either 10 or 63 μg vitamin D/d is sufficient to maintain the calcium balance. This trial was registered at clinicaltrials.gov as NCT00473031.
The Bone, Exercise, Alendronate, and Caloric Restriction (BEACON) trial design and methods.
Beavers K, Wolle B, Ard J, Beavers D, Biehl O, Brubaker P Contemp Clin Trials. 2024; 146():107692.
PMID: 39293778 PMC: 11531379. DOI: 10.1016/j.cct.2024.107692.
The effects of popular diets on bone health in the past decade: a narrative review.
Peng Y, Zhong Z, Huang C, Wang W Front Endocrinol (Lausanne). 2024; 14:1287140.
PMID: 38665424 PMC: 11044027. DOI: 10.3389/fendo.2023.1287140.
New Insights into Calorie Restriction Induced Bone Loss.
Liu L, Rosen C Endocrinol Metab (Seoul). 2023; 38(2):203-213.
PMID: 37150516 PMC: 10164494. DOI: 10.3803/EnM.2023.1673.
Cruz S, de Matos A, da Cruz S, Pereira S, Saboya C, Ramalho A Biomedicines. 2023; 11(1).
PMID: 36672594 PMC: 9855429. DOI: 10.3390/biomedicines11010086.
Optimal Serum 25(OH)D Level and Vitamin D Intake in Young Korean Women.
Shin H, Park H, Ly S Nutrients. 2022; 14(22).
PMID: 36432534 PMC: 9698687. DOI: 10.3390/nu14224845.